CHOSOURCE GS KO cell line
The CHOSOURCE Glutamine Synthetase (GS) knockout (KO) cell line is a well-established, cGMP-manufactured, robust cell line. Generated from CHO-K1 cells with the GS gene knocked out using precision rAAV technology.
With proven performance, the CHOSOURCE GS KO cell line comes with a comprehensive cell history package and protocols to support you throughout the process of research, development, and regulatory filing of a biotherapeutic.
CHOSOURCE ADCC+ cell line
The glycoengineered CHOSOURCE GS KO cell line for enhanced antibody-dependent cellular cytotoxicity (ADCC) activity offers fully afucosylated antibodies, Fc-fusions, and other therapeutic proteins for increased therapeutic efficacy and potency.
Experience full control over biopharmaceutical potency with the CHOSOURCE ADCC+ Cell Line. Developed from the CHOSOURCE GS KO cell line, this cell line ensures controlled product quality (100% fucose-free) and expand therapeutic applications by enhancing the therapeutic window and broadening the patient population.
CHOSOURCE TnT transposon technology
The CHOSOURCE TnT transposon expression system offers a safe and reliable technology for the generation of stable expressing clones. This system provides faster development timelines and high reproducibility across pools and clones to help accelerate cell line development programs.
The two-component expression system, which includes the TnT transposon vector and TnT transposase mRNA, is optimized for use with CHOSOURCE cell lines.
The robustness and reliability of CHOSOURCE TnT make it an exceptional tool for streamlining development and manufacturing processes, with the potential to enable new paradigms that can expedite preclinical and clinical development.
Bioproduction Cell Line Engineering Services
Partner with the right gene editing experts to aid your biotherapeutic development with custom editing of bioproduction cell lines. We’re able to support your specific manufacturing needs for protein and viral vector therapeutics with over 10 years’ worth of experience in gene editing for biotherapeutic manufacturing.
Benefit from a track record of >70 global regulatory filings, an advanced CRISPR-based platform, multiple editing capabilities, and fully traceable documented history.
CHOSOURCE customer testimonials
The CHOSOURCE expression platform has been licensed globally over 100 times, ranging from academia to large pharma and biotech, as well as small to large CDMOs. Hear from some of these customers in regards to how they implemented the CHOSOURCE platform, how the platform is able to be tailored to meet their unique needs, and the flexible licensing terms that can be fitted to their requirements.
The CHOSOURCE™ Platform is available for research, clinical, diagnostic, and commercialization applications under specific licenses from Revvity. The platform is also available for services under a service license from Revvity.